secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001753926-24-000691
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell updates on $6.6M IPO, pipeline progress, and liability reduction
---------------------------------------------------------------------------

- Closed IPO Feb 21, 2024, gross proceeds ~$6.6M; all pre-IPO debt and Series A preferred converted.
- Removed ~$2.7M in liabilities via Series C preferred issuance and CEO compensation deferral.
- Lead candidate CC8464 completed Phase I (no euphoria, 4% rash incidence); slow dose escalation planned before Phase II.
- New eye pain program CT2000 launched; Dr. Simon Chandler hired; animal toxicity studies expected H2 2024.
- 10-K delayed due to IPO workload; expects filing within permitted 15-day extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/0001753926-24-000691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/g084169_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer